David P. Dearnaley

38.9k citations

416 papers · 18.4k indexed · 5 hit papers · h-index 73

Impact in

Radiation top 0.02%
- Advanced Radiotherapy Techniques
Pulmonary and Respiratory Medicine top 0.05%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Radiation Therapy and Dosimetry

Papers in

Radiation 129
- Advanced Radiotherapy Techniques 129
Pulmonary and Respiratory Medicine 307
- Prostate Cancer Treatment and Research 207
- Prostate Cancer Diagnosis and Treatment 180
- Radiation Therapy and Dosimetry 26

Co-authors: Robert Huddart Vincent Khoo A. Norman A. Horwich Alan Horwich Chris Parker Matthew R. Sydes Christopher M. Nutting
Journals: Journal of Clinical Oncology (53 papers)Radiotherapy and Oncology (48 papers)International Journal of Radiation Oncology*Biology*Physics (47 papers)Clinical Oncology (40 papers)British Journal of Cancer (21 papers)
Partner nations: United Kingdom United States Canada

In The Last Decade

David P. Dearnaley

403 papers receiving 17.9k citations

Hit Papers

5 papers align trajectories log scale

Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial 2014 · 344 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2014 The Lancet Oncology
2012 The Lancet Oncology
2008 Journal of Clinical Oncology
2007 The Lancet Oncology
1999 The Lancet

Peers

Countries citing papers authored by David P. Dearnaley

Since Specialization

Citations

This map shows the geographic impact of David P. Dearnaley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David P. Dearnaley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David P. Dearnaley more than expected).

Fields of papers citing papers by David P. Dearnaley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David P. Dearnaley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David P. Dearnaley. The network helps show where David P. Dearnaley may publish in the future.

Co-authors

The 25 scholars most cited alongside David P. Dearnaley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David P. Dearnaley Line = papers co-authored together David P. Dearnaley links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials Journal of Clinical Oncology ·Lucia Kwak, Praful Ravi, John G. Armstrong, V. Beckendorf, Joseph L. Chin, Anthony V. D’Amico, David P. Dearnaley, Savino M. Di Stasi, Silke Gillessen, Himanshu Lukka, Nicolas Mottet, P. Pommier, Wendy Seiferheld, Matthew R. Sydes, Bertrand Tombal, A. Zapatero, Meredith M. Regan, Wanling Xie, Christopher J. Sweeney	2024	6
2	Gastrointestinal Toxicity Prediction Not Influenced by Rectal Contour or Dose-Volume Histogram Definition International Journal of Radiation OncologyBiologyPhysics ·Douglas Brand, Sarah C. Brüningk, Anna Wilkins, Olivia Naismith, Annie Gao, Isabel Syndikus, David P. Dearnaley, Emma Hall, Nicholas van As, Alison Tree, S. Gulliford	2023	1
3	International Society of Urological Pathology ( ISUP) Gleason Grade Groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trial British Journal of Urology ·David P. Dearnaley, Clare Griffin, Pedro Leme Silva, Anna Wilkins, 沼寿隆, Isabel Syndikus, Shama Hassan, Julia Pugh, Clare Cruickshank, Emma Hall, Catherine M. Corbishley	2023	2
4	Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation EBioMedicine ·Anna Wilkins, Barry A. Gusterson, Holly Tovey, Clare Griffin, 沼寿隆, Frances Daley, Catherine M. Corbishley, David P. Dearnaley, Emma Hall, Navita Somaiah	2023	5
5	Relugolix, An Oral Gonadotropin-Releasing Hormone Antagonist for the Treatment of Prostate Cancer Future Oncology ·Daniel J. George, David P. Dearnaley	2021	5
6	Derivation of Dose/Volume Constraints for the Anorectum from Clinician- and Patient-Reported Outcomes in the CHHiP Trial of Radiation Therapy Fractionation International Journal of Radiation OncologyBiologyPhysics ·Anna Wilkins, Olivia Naismith, Douglas Brand, V K Katyal, Emma Hall, David P. Dearnaley, S. Gulliford	2020	31
7	Microbiota- and Radiotherapy-Induced Gastrointestinal Side-Effects (MARS) Study: A Large Pilot Study of the Microbiome in Acute and Late-Radiation Enteropathy Clinical Cancer Research ·Miguel Reis Ferreira, Jervoise Andreyev, Kabir Mohammed, Xu Shu, Sharon Gowan, Jia Li, S. Gulliford, Julian R. Marchesi, David P. Dearnaley	2019	138
8	Seven or less Fractions is Not the Standard of Care for Intermediate-Risk Prostate Cancer Clinical Oncology ·Alison Tree, David P. Dearnaley	2019	3
9	Forward- and Inverse-Planned Intensity-Modulated Radiotherapy in the CHHiP Trial: A Comparison of Dosimetry and Normal Tissue Toxicity Clinical Oncology ·Olivia Naismith, Clare Griffin, Isabel Syndikus, C. South, Helen Mayles, Philip Mayles, Vincent Khoo, Christopher Scrase, John D. Graham, Shama Hassan, Emma Hall, David P. Dearnaley	2019	3
10	Patterns of recurrence after prostate bed radiotherapy Radiotherapy and Oncology ·Douglas Brand, 刘永茂, David P. Dearnaley, Rosalind A. Eeles, Robert Huddart, Vincent Khoo, Julia Murray, Yae‐Eun Suh, Alison Tree, Nicholas van As, Chris Parker	2019	15
11	Validation of T2- and diffusion-weighted magnetic resonance imaging for mapping intra-prostatic tumour prior to focal boost dose-escalation using intensity-modulated radiotherapy (IMRT) Radiotherapy and Oncology ·Baljinder Randhawa, Julia Murray, Veronica A. Morgan, Sharon Giles, Sophie F. Riches, Rafatpanah Houshang, Karen Thomas, S.A. Sohaib, Alan Thompson, Fatemeh Namaki, David P. Dearnaley, Nandita M. deSouza	2019	10
12	Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancer Clinical and Translational Radiation Oncology ·Anna Wilkins, 沼寿隆, Shama Hassan, Claire Blanchard, Clare Cruickshank, Clare Griffin, Muḥammad Adīb Jādir, Catherine M. Corbishley, Chris Parker, David P. Dearnaley, Emma Hall	2018	1
13	Iterative framework for the joint segmentation and CT synthesis of MR images: application to MRI-only radiotherapy treatment planning Physics in Medicine and Biology ·Ninon Burgos, Filipa Guerreiro, Jamie R. McClelland, Benoît Presles, Marc Modat, Simeon Nill, David P. Dearnaley, Nandita M. deSouza, Uwe Oelfke, Antje Knopf, Sébastien Ourselin, M. Jorge Cardoso	2017	28
14	Frequency of Screening Magnetic Resonance Imaging to Detect Occult Spinal Cord Compromise and to Prevent Neurological Deficit in Metastatic Castration-resistant Prostate Cancer Clinical Oncology ·KuanShuo Dong, S.A. Sohaib, Yolanda Barbáchano, Chris Parker, Robert Huddart, Alan Horwich, David P. Dearnaley	2010	16
15	Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven Journal of Clinical Oncology ·Gerhardt Attard, Alison Reid, Timothy A. Yap, Florence I. Raynaud, Mitch Dowsett, S. Settatree, Mary Barrett, Christopher Parker, Vanessa Martins, Elizabeth Folkerd, J. W. Clark, Colin S. Cooper, Stan B. Kaye, David P. Dearnaley, Gloria Lee, Johann S. de Bono Hit paper breakdown →	2008	666
16	Selective inhibition of CYP17 with abiraterone acetate is well tolerated and results in a high response rate in castration-resistant prostate cancer (CRPC) Molecular Cancer Therapeutics ·Gerhardt Attard, Alison Reid, Rajesh Kumar Sinha, R. Molife, Florence I. Raynaud, Mitch Dowsett, Mary Barrett, Emilda Thompson, Timothy A. Yap, S. Settatree, Vanessa Martins, Christopher Parker, David P. Dearnaley, Elizabeth Folkerd, Gloria Lee, Johann S. de Bono	2007	1
17	Target Volume Definition for Intensity Modulated Whole Pelvic Radiotherapy (IMWPRT) International Journal of Radiation OncologyBiologyPhysics ·J. Staffurth, Elizabeth Adams, Stephen Breen, Aslam Sohaib, Robert Huddart, David P. Dearnaley	2005	5
18	The Potential Use of ^99m Tc-MDP Bone Scans to Plan High-Activity ¹⁸⁶ Re-HEDP Targeted Therapy of Bony Metastases from Prostate Cancer Cancer Biotherapy and Radiopharmaceuticals ·Claunice Maria Dorneles, Carine Vinardi, V. R. McCready, David P. Dearnaley, Glenn Flux	2005	3
19	Quantitative analysis of bone scans to determine if the dose to individual metastases from high activity Re186HEDP therapy depends upon the number of metastases Radiology ·V. R. McCready, Joe M. O’Sullivan, David P. Dearnaley, J. Treleaven	2001	1
20	Use of antisera to epithelial membrane antigen for the cytodiagnosis of malignancy in serous effusions. Journal of Clinical Pathology ·A To, D. V. Coleman, David P. Dearnaley, M.G. Ormerod, Kate Steele, Alan Nevill	1981	64

About David P. Dearnaley

David P. Dearnaley is a scholar working on Radiation, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Oncology and Cancer Research, having authored 416 papers that have together received 18.4k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (207 papers), Prostate Cancer Diagnosis and Treatment (180 papers), Advanced Radiotherapy Techniques (129 papers), Radiopharmaceutical Chemistry and Applications (39 papers), Testicular diseases and treatments (33 papers), Bladder and Urothelial Cancer Treatments (28 papers), Cancer, Lipids, and Metabolism (28 papers) and Radiation Therapy and Dosimetry (26 papers). The work is most often cited by research in Radiation (4.6k citations), Pulmonary and Respiratory Medicine (11.3k citations), Radiology, Nuclear Medicine and Imaging (5.0k citations), Oncology (3.7k citations) and Cancer Research (1.9k citations). David P. Dearnaley has collaborated with scholars based in United Kingdom, United States and Canada. Frequent co-authors include Robert Huddart, Vincent Khoo, A. Norman, A. Horwich, Alan Horwich, Chris Parker, Matthew R. Sydes, Christopher M. Nutting, J. Nicholls and Johann S. de Bono. Their work appears in journals such as Journal of Clinical Oncology, Radiotherapy and Oncology, International Journal of Radiation Oncology*Biology*Physics, Clinical Oncology and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact